Cargando...
Profile of suvorexant in the management of insomnia
Suvorexant, approved in late 2014 in the United States and Japan for the treatment of insomnia characterized by difficulty achieving and/or maintaining sleep, is a dual orexin receptor antagonist and the first drug in its class to reach the market. Its development followed from the 1998 discovery of...
Guardado en:
| Publicado en: | Drug Des Devel Ther |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4651361/ https://ncbi.nlm.nih.gov/pubmed/26648692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S73224 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|